Given the role of TGF‐β and Hh signalling in fibrogenesis, Oxy210 has the potential to be a drug candidate for fibrotic diseases of non‐NASH aetiology and/or other organ systems (such as pulmonary and renal fibrosis). Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.